HA
GILD icon

Hofer & Associates’s Gilead Sciences GILD Stock Holding History

Hofer & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$252K Buy
1,996
+69
+4% +$9.09K 0.12% 60
2026
Q1 		$269K Buy
1,927
+24
+1% +$3.36K 0.14% 52
2025
Q4 		$234K Buy
+1,903
New +$231K 0.12% 61

Other funds holding GILD

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Hofer & Associates's GILD Position: Q2 2026 in Review

Hofer & Associates increased its Gilead Sciences (GILD) stake by 3.6% in Q2 2026, buying an estimated $9.09K and bringing the position to 1,996 shares worth $252K. The position accounts for 0.12% of the portfolio, ranked #60.

Hofer & Associates first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $269K in Q1 2026. 837 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Hofer & Associates held 1,996 shares of Gilead Sciences worth $252K as of Q2 2026.
  • Hofer & Associates bought 69 Gilead Sciences shares in Q2 2026, an estimated $9.09K.
  • Gilead Sciences made up 0.12% of Hofer & Associates's portfolio in Q2 2026, its #60 holding.
  • Hofer & Associates first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Hofer & Associates's Gilead Sciences position peaked at $269K in Q1 2026.
  • 837 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Hofer & Associates's 13F filing for Q2 2026, filed 21 Jul 2026.